Cargando…
OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia
Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes related to inadequate glucocorticoid (GC) replacement. We compared disease control of adults with classic CAH treated with a modified release hydrocortisone (MRHC), which...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209435/ http://dx.doi.org/10.1210/jendso/bvaa046.214 |
_version_ | 1783531077242978304 |
---|---|
author | Merke, Deborah P Mallappa, Ashwini Arlt, Wiebke de la Perriere, Aude Brac Hirschberg, Angelica Linden Juul, Anders Newell-Price, John D C Perry, Colin Graham Prete, Alessandro Rees, Aled Reisch, Nicole Stikkelbroeck, Monica Touraine, Philippe A Maltby, Kerry Treasure, Peter Porter, John Ross, Richard John M |
author_facet | Merke, Deborah P Mallappa, Ashwini Arlt, Wiebke de la Perriere, Aude Brac Hirschberg, Angelica Linden Juul, Anders Newell-Price, John D C Perry, Colin Graham Prete, Alessandro Rees, Aled Reisch, Nicole Stikkelbroeck, Monica Touraine, Philippe A Maltby, Kerry Treasure, Peter Porter, John Ross, Richard John M |
author_sort | Merke, Deborah P |
collection | PubMed |
description | Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes related to inadequate glucocorticoid (GC) replacement. We compared disease control of adults with classic CAH treated with a modified release hydrocortisone (MRHC), which replicates physiological diurnal cortisol secretion, versus standard GC therapy. Methods: 6 month, open label, study in 122 patients randomised either to treatment with MRHC (Chronocort®, Diurnal Ltd, Cardiff, UK) twice daily at ~ 0700h & ~2300h, or to remain on their standard GC regimen (hydrocortisone, prednisolone, prednisone, dexamethasone). Patients had 24-hr profiling of serum 17-hydroxyprogesterone (17-OHP) at baseline and for dose titration at 4 and 12 weeks. The primary efficacy endpoint was the change from baseline to 24 weeks in the natural logarithm of the mean of the 24-hr standard deviation score (SDS) profile for 17-OHP. Results: Both groups achieved improved hormonal control at 24 weeks. The mean 24-hour 17-OHP SDS was significantly lower on MRHC compared to standard GC at 4 weeks (p = 0.0074) and 12 weeks (p = 0.019), but not at 24 weeks. In post-hoc analyses at 24 weeks, MRHC treatment showed a greater reduction in 17-OHP SDS compared to standard GC in the morning, 0700-1500h (p = 0.0442) and a greater reduction in log transformed 17-OHP 24 hour AUC (p=0.0251). Defining a morning 17-OHP <1200ng/dl (<36 nmol/L) as good control, for patients not controlled at baseline 85% were well controlled at 24 weeks with MHRC versus 50% on standard GC. For patients controlled at baseline 100% were controlled at 24 weeks on MHRC versus 84% with standard GC (p = 0.0018). The variability of 17-OHP over 24 hours was significantly reduced in the MRHC group compared to standard GC: the ratio of amplitude at 24 weeks divided by amplitude at baseline was for MRHC, 0.361 [95% CI: 0.235, 0.651], and standard GC, 0.917 [0.773, 1.366]; (p = 0.0001).There were no adrenal crises on MRHC and fewer stress doses despite similar incidence of inter-current illness to the standard GC group which had 3 adrenal crises. MRHC was associated with patient reported benefit including restoration of menstruation in 4 patients on MRHC and 1 on standard GC and two partner pregnancies in patients on MRHC and none on standard GC. Discussion: This is the largest randomised controlled trial of GC treatment in CAH and showed that intensification of therapy could improve control of the androgen-precursor, 17-OHP, and that this hormonal control was superior in the morning with MRHC. MRHC reduced the fluctuations in 17-OHP such that in the majority of patients the 17-OHP profile was within the reference range throughout 24 hours, providing consistent and optimal disease control. Conclusion: Diurnal cortisol replacement with a MRHC improves the biochemical control of classic CAH with a twice-daily therapeutic regimen. |
format | Online Article Text |
id | pubmed-7209435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72094352020-05-13 OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia Merke, Deborah P Mallappa, Ashwini Arlt, Wiebke de la Perriere, Aude Brac Hirschberg, Angelica Linden Juul, Anders Newell-Price, John D C Perry, Colin Graham Prete, Alessandro Rees, Aled Reisch, Nicole Stikkelbroeck, Monica Touraine, Philippe A Maltby, Kerry Treasure, Peter Porter, John Ross, Richard John M J Endocr Soc Adrenal Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes related to inadequate glucocorticoid (GC) replacement. We compared disease control of adults with classic CAH treated with a modified release hydrocortisone (MRHC), which replicates physiological diurnal cortisol secretion, versus standard GC therapy. Methods: 6 month, open label, study in 122 patients randomised either to treatment with MRHC (Chronocort®, Diurnal Ltd, Cardiff, UK) twice daily at ~ 0700h & ~2300h, or to remain on their standard GC regimen (hydrocortisone, prednisolone, prednisone, dexamethasone). Patients had 24-hr profiling of serum 17-hydroxyprogesterone (17-OHP) at baseline and for dose titration at 4 and 12 weeks. The primary efficacy endpoint was the change from baseline to 24 weeks in the natural logarithm of the mean of the 24-hr standard deviation score (SDS) profile for 17-OHP. Results: Both groups achieved improved hormonal control at 24 weeks. The mean 24-hour 17-OHP SDS was significantly lower on MRHC compared to standard GC at 4 weeks (p = 0.0074) and 12 weeks (p = 0.019), but not at 24 weeks. In post-hoc analyses at 24 weeks, MRHC treatment showed a greater reduction in 17-OHP SDS compared to standard GC in the morning, 0700-1500h (p = 0.0442) and a greater reduction in log transformed 17-OHP 24 hour AUC (p=0.0251). Defining a morning 17-OHP <1200ng/dl (<36 nmol/L) as good control, for patients not controlled at baseline 85% were well controlled at 24 weeks with MHRC versus 50% on standard GC. For patients controlled at baseline 100% were controlled at 24 weeks on MHRC versus 84% with standard GC (p = 0.0018). The variability of 17-OHP over 24 hours was significantly reduced in the MRHC group compared to standard GC: the ratio of amplitude at 24 weeks divided by amplitude at baseline was for MRHC, 0.361 [95% CI: 0.235, 0.651], and standard GC, 0.917 [0.773, 1.366]; (p = 0.0001).There were no adrenal crises on MRHC and fewer stress doses despite similar incidence of inter-current illness to the standard GC group which had 3 adrenal crises. MRHC was associated with patient reported benefit including restoration of menstruation in 4 patients on MRHC and 1 on standard GC and two partner pregnancies in patients on MRHC and none on standard GC. Discussion: This is the largest randomised controlled trial of GC treatment in CAH and showed that intensification of therapy could improve control of the androgen-precursor, 17-OHP, and that this hormonal control was superior in the morning with MRHC. MRHC reduced the fluctuations in 17-OHP such that in the majority of patients the 17-OHP profile was within the reference range throughout 24 hours, providing consistent and optimal disease control. Conclusion: Diurnal cortisol replacement with a MRHC improves the biochemical control of classic CAH with a twice-daily therapeutic regimen. Oxford University Press 2020-05-08 /pmc/articles/PMC7209435/ http://dx.doi.org/10.1210/jendso/bvaa046.214 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Adrenal Merke, Deborah P Mallappa, Ashwini Arlt, Wiebke de la Perriere, Aude Brac Hirschberg, Angelica Linden Juul, Anders Newell-Price, John D C Perry, Colin Graham Prete, Alessandro Rees, Aled Reisch, Nicole Stikkelbroeck, Monica Touraine, Philippe A Maltby, Kerry Treasure, Peter Porter, John Ross, Richard John M OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia |
title | OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia |
title_full | OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia |
title_fullStr | OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia |
title_full_unstemmed | OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia |
title_short | OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia |
title_sort | or25-02 a phase 3 study of a modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia |
topic | Adrenal |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209435/ http://dx.doi.org/10.1210/jendso/bvaa046.214 |
work_keys_str_mv | AT merkedeborahp or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT mallappaashwini or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT arltwiebke or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT delaperriereaudebrac or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT hirschbergangelicalinden or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT juulanders or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT newellpricejohndc or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT perrycolingraham or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT pretealessandro or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT reesaled or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT reischnicole or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT stikkelbroeckmonica or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT tourainephilippea or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT maltbykerry or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT treasurepeter or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT porterjohn or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia AT rossrichardjohnm or2502aphase3studyofamodifiedreleasehydrocortisoneinthetreatmentofcongenitaladrenalhyperplasia |